CA
NZ
UK
AU
IND
US
The Centers for Medicare and Medicaid Services released its 2027 Star Ratings after the close on October 8, 2026. The ratings grade Medicare Advantage plans on quality and service from one to five stars, and plans rated 4 or higher qualify for quality bonus …
Two FDA dates are close. Enspryng, a Roche medicine, has a decision date of October 15, 2026, and the phentolamine ophthalmic solution being developed by Opus Genetics with Viatris (NASDAQ:VTRS) has a date of October 17. A third item, the Daiichi Sankyo and MerckBiologicslicense …
XORTX Therapeutics (NASDAQ:XRTX) said it has received more inquiries about commercialization and has made progress on a trial application with Health Canada, according to a company release reported around October 9, 2026. The stock rose about 22% after hours. The company's market capitalization is …
Exchange market data for October 8, 2026 showed a group of large gainers. Pacira rose about 44%, Fly-E 83%, Jianzhi Education 77%, Xiao-I 46% and Haemonetics 17.5%. Surrozen (NASDAQ:SRZN) climbed 11.2% to 27.97 and was grouped with them, alongside a 16.4% move in Cable …
Humana (NYSE:HUM) was up about 15% in premarket trading on October 9, 2026, according to a movers list. Different recaps give 12% after hours, 14.95% premarket and 16.5%, a spread that reflects timing and venue. The file does not name the catalyst, so none …
The clearest catalyst of the group is a government ratings decision. Humana (NYSE:HUM) was up 14.82% in premarket trading on October 9, 2026 on a listed price of USD 387.12 and aMarket Valueof about USD 46.49 billion. The Centers for Medicare and Medicaid Services …
Humana (NYSE:HUM) was up about 15% in premarket trading on October 9, 2026, according to a movers list. Different recaps give 12% after hours, 14.95% premarket and 16.5%, which is a spread explained by timing and venue. The file does not name the catalyst, …
Atrium is the only name with a same-week financing. Atrium Therapeutics (NASDAQ:RNA) was down 3.15% in premarket trading on October 9, 2026 on a listed price of USD 8.26. On October 8 the company announced a privatePlacementof about USD 50 million: 5,170,384 shares at …
Humana (NYSE:HUM) was indicated up 14.82% in the October 9, 2026 premarket session, based on a listed price of USD 387.12 on the premarket screener. Published reports tie the move to the Centers for Medicare and Medicaid Services 2027 Star Ratings, released on October …
Pfizer (NYSE:PFE) said the FDA approved Tukysa, known generically as tucatinib, as first-line maintenance treatment in HER2-positive breast cancer. The supporting figure is progression-free survival of 24.9 months versus 16.3 months, an 8.6-month gap by simple arithmetic on two published numbers. Progression-free survival measures …
Please wait processing your request...